Arcadia Biosciences, Inc.
RKDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -5.42% | -34.50% | -39.14% | -27.36% |
| EV / EBITDA | 4.22 | -3.05 | -0.76 | -1.77 |
| Quality | ||||
| ROIC | -18.29% | -8.41% | 4.91% | -20.51% |
| Gross Margin | 32.10% | 43.37% | 43.17% | 31.99% |
| Cash Conversion Ratio | -0.30 | 0.46 | -0.61 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.33% | 1.98% | -11.78% | -19.43% |
| Free Cash Flow Growth | 87.36% | -28.02% | 28.11% | -26.08% |
| Safety | ||||
| Net Debt / EBITDA | -1.31 | 0.92 | 2.60 | 1.81 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.61 | 0.55 | 0.53 | 0.91 |
| Cash Conversion Cycle | 0.63 | 70.65 | 187.93 | 108.84 |